Initiatives to increase the prescribing of low cost generics : the case of Scotland in the international context by Godman, Brian et al.
Godman, Brian and Kurdi, Amanj and Leporowski, Axel and Morton, Alec 
and Baumgärtel, Christoph and Bochenek, Tomasz and Fadare, Joseph 
and Finlayson, Alexander and Hussein, Shazhad and Khan, Babar and 
Kalaba, Marija and Kibuule, Dan and Kwon, Hye-Young and Melien, 
Oyvind and Nascimento, Renata CRM and Salem, Ahmed and Schiffers, 
Krijn and Truter, Ilse and Voncina, Luka and Hassali, Azmi (2017) 
Initiatives to increase the prescribing of low cost generics : the case of 
Scotland in the international context. Medical Research Archives, 5 (3). 
ISSN 2375-1924 , 10.18103/mra.v5i3.1071
This version is available at http://strathprints.strath.ac.uk/59768/
Strathprints is  designed  to  allow  users  to  access  the  research  output  of  the  University  of 
Strathclyde. Unless otherwise explicitly stated on the manuscript, Copyright © and Moral Rights 
for the papers on this site are retained by the individual authors and/or other copyright owners. 
Please check the manuscript for details of any other licences that may have been applied. You 
may  not  engage  in  further  distribution  of  the  material  for  any  profitmaking  activities  or  any 
commercial gain. You may freely distribute both the url (http://strathprints.strath.ac.uk/) and the 
content of this paper for research or private study, educational, or not-for-profit purposes without 
prior permission or charge. 
Any correspondence concerning this service should be sent to the Strathprints administrator: 
strathprints@strath.ac.uk
The Strathprints institutional repository (http://strathprints.strath.ac.uk) is a digital archive of University of Strathclyde research 
outputs. It has been developed to disseminate open access research outputs, expose data about those outputs, and enable the 
management and persistent access to Strathclyde's intellectual output.
  
 
Initiatives to increase the prescribing of low cost generics; the case of Scotland in the 
international context 
 
Authors 
Brian Godman1,2, Amanj Baker2, Axel 
Leporowski3,4, Alec Morton4, Christoph 
Baumgärtel5, Tomasz Bochenek6, Joseph 
Fadare7, Alexander Finlayson8, Shazhad 
Hussain9, Babar Khan10, Marija Kalaba11, 
Dan Kibuule12, Hye-Young Kwon13, Oyvind 
Melien14, Renata CRM Nascimento15, 
Ahmed Salem16, Krijn Schiffers17, Ilse 
Truter18, Luka Voncina19, Mohamed Azmi 
Hassali20 
 
Affiliations 
1. Division of Clinical Pharmacology, 
Karolinska University Hospital 
Huddinge, Institutet, Stockholm, 
Sweden 
 
2. Strathclyde Institute of Pharmacy and 
Biomedical Sciences, Strathclyde 
University, Glasgow, UK 
 
3. Strathclyde Business School, 
Strathclyde University, Glasgow, UK 
 
4. Alfred-Weber-Institut für 
Wirtschaftswissenschaften, Ruprecht- 
Karls-Universität  Heidelberg, Germany 
 
5. AGES Austrian Medicines and 
Medical Devices Agency and Austrian 
Federal Office for Safety in Health 
Care, Traisengasse, Vienna, Austria. 
 
6. Department of Drug Management, 
Faculty of Health Sciences, 
Jagiellonian University Medical 
College, Krakow, Poland 
 
7. Department of Pharmacology, Ekiti 
State University, Ado-Ekiti, Nigeria. 
 
8. Nuffield Department of Primary Care 
Health Sciences, University of Oxford, 
Oxford, UK 
 
9. National Institute of Health, Islamabad, 
Pakistan. 
10. Department of Pharmacy, University of 
Lahore, Islamabad Campus, Pakistan 
 
11. The Institute for Medical Care of 
Mother and Child of Serbia "Dr 
VukanCupic", RadojaDakića, 
Belgrade, Serbia 
 
12. School of Pharmacy, Department of 
Pharmacy Practice and Policy, Faculty 
of Health Sciences, University of 
Namibia, Windhoek, Namibia 
 
13. Mokwon University, Division of 
Biology & Public Health, Daejeon, 
South Korea 
 
14. Health Directorate, Ministry of Health, 
Oslo, Norway. Email: 
oyvind.melien@helsedir.no 
 
15. Pharmacy College, Federal University 
of Minas Gerais (UFMG), Belo 
Horizonte, Minas Gerais, Brazil 
 
16. QuintilesIMS, Brussels, Belgium 
 
17. Ecorys Nederland B.V., Rotterdam, the 
Netherlands. 
 
18. Drug Utilization Research Unit 
(DURU), Department of Pharmacy, 
Nelson Mandela Metropolitan 
University (NMMU), Port Elizabeth, 
South Africa. 
 
19. Independent Consultant, Zagreb, 
Croatia. 
 
20. Discipline of Social and 
Administrative Pharmacy, School of 
Pharmaceutical Sciences, Universiti 
Sains Malaysia, Penang, Malaysia. 
 
Correspondence 
 
Brian Godman 
Email: Brian.Godman@ki.se 
  
 
Abstract 
 
Getting the most out of the pharmaceutical 
budget is critical across all countries as the 
financial pressures on healthcare systems 
intensify. In this paper, we review global 
practice on encouraging the use of low costs 
generics versus branded pharmaceuticals, 
including patented products in the same class 
where care is not compromised, across 
countries to guide future practice. Our 
review ranges widely across European 
countries as well as other high income 
countries, including Abu Dhabi, Japan and 
the USA, and other low and middle income 
countries. There is a particular focus on 
Scotland, building on previous publications. 
We conclude based on multiple publications, 
including several case studies, that achieving 
efficiency in pharmaceutical spending is 
possible in virtually all environments, 
although there are examples of technologies 
where generic or therapeutic substitution 
should not be encouraged. However, there is 
no magic bullet to achieving full and 
appropriate use of generics. Countries have 
to be prepared to use a number of different 
education, economic, engineering and 
enforcement methods including prescribing 
restrictions to achieve success. Similarly, 
different approaches to achieve low prices 
for good quality generics given the 
considerable price differences that currently 
exist. The combination of low prices and 
increased use of generics will help achieve or 
attain universal healthcare, benefiting all key 
stakeholder groups. We conclude with a call 
for greater cross-country learning in pursuit 
of what should be a common goal for all 
health systems. 
 
Keywords: Co-payments, compulsory 
substitution, generics, prescribing 
restrictions, prices, reforms, Scotland 
international context 
 
 
 
1. Introduction 
 
Increasing the prescribing and dispensing of 
generics versus originators, or patented 
products in a class where care is not 
compromised, is essential to enhance access 
to medicines as well as, maintain or attain 
comprehensive healthcare given ever 
increasing resource pressures (1-3). We are 
now seeing even high income countries 
struggling to fund new valued premium 
priced medicines (2, 4). As the population 
ages, this phenomenon will worsen unless 
adequately addressed (1, 5). Increasing the 
prescribing and dispensing of generics is 
particularly important in lower and middle 
income countries (LMICs) where up to 70% 
of total healthcare costs are spent on 
medicines; a significant proportion of which 
can be out-of-pocket, and where 
considerable savings can be made (6-9). 
Lowering the prices of generics among 
Central and Eastern European countries can 
also be beneficial, especially where co- 
payments are high and a barrier to 
appropriate care (10). 
 
The availability of generic antiretroviral 
(ARVs) medicines are of particular 
importance in LMICs, especially in sub- 
Saharan countries, where up to 69% of the 
34 million worldwide cases of HIV 
currently reside and where 41% of the 
population currently live on less than 
US$1.25 per day (11-15). Studies have 
shown that the availability of generic ARVs 
not only decreases the costs of treatment, 
but has a positive impact on treatment 
compliance, leading to decreased morbidity, 
mortality and rates of transmission (16-19). 
The cost of highly active antiretroviral 
therapy (HAART) decreased 20-fold after 
generic HAART in India, with a 5 fold 
reduction in mortality (20). Increased access 
to generic antibiotics has also helped 
combat infection in many LMICs (21); 
however, increasing antibiotic availability 
has increased resistance rates (22). 
 
The increasing availability of low cost 
generics for patients with cancer, including 
novel cancer medicines such as the tyrosine 
kinase inhibitors, will also increase the 
number of patients that can be effectively 
treated (23, 24). In addition, help address 
health authority concerns with ever 
increasing prices for new cancer medicines, 
which are now threatening access for 
patients and the sustainability of healthcare 
systems (23, 25-27). However, the 
availability of sub-standard generic cancer 
medicines is a concern to physicians, 
patients and health service managers, which 
needs to be addressed (24). 
 
Low cost generics can also help increase 
adherence to medicines, with adherence 
critical for the effective treatment of chronic 
diseases including HIV as well as non- 
communicable diseases (NCDs) such as 
diabetes, hypercholesterolaemia and arterial 
hypertension (28-34). Adherence is 
negatively affected not only by the 
complexity of prescribed drug regimens, 
their safety or tolerability, but also by issues 
of co-payments in a number of countries as 
well as health care systems (35-46). 
 
Recent publications have demonstrated 
similar effectiveness between generics and 
originators across a range of molecules and 
disease areas (46-60), and addressed 
concerns even where different salts have 
been used for generics, e.g. generic 
clopidogrel (61). However, concerns still 
exist about the quality of generics and their 
effectiveness, especially in some classes and 
countries, as well as issues with substitution 
impacting on potential savings (3, 8, 24, 62- 
77). This includes concerns with generic 
lopinavir/ ritonavir in recent years, which is 
the cornerstone of second-line ARVs (11), 
resulting in suggestions for dynamic 
ongoing surveillance. Concerns with the 
quality of generics has also resulted in 
suggestions  for  better  monitoring  of   the 
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ingredients as seen recently in Pakistan (78). 
Key stakeholder concerns with substitution 
with a limited number of molecules has 
resulted in countries, including Sweden and 
the United Kingdom (UK), issuing guidance 
on which molecules should not be 
substituted (Box 1 Section 3.2.2), with the 
Royal Dutch Pharmacists Association 
issuing similar guidance to their members 
(79-82). There is now less concern with 
substituting generic immunosuppressive 
medicines than originally thought (83, 84). 
However, care is needed regarding potential 
strategies and their outcome with a recent 
systematic review on generic substitution 
demonstrating that that while health 
outcomes appear similar following 
substitution, the full extent of potential 
savings are not guaranteed (85). 
 
There have been concerns among health 
authorities if pharmaceutical companies 
heavily discount prices of their branded 
medicines in hospitals with the expectation 
that patients will be discharged on more 
expensive medicines, greatly increasing 
costs in ambulatory care (86-88). In 
addition, if companies launch patented 
follow-on products just before patent expiry 
of the initial molecule to limit revenue loss, 
referred to as „evergreening strategies‟ (89). 
There are also concerns if pharmaceutical 
companies pay generic companies to delay 
launching their generics, as well as 
instigating other tactics such as product 
hopping, to try and reduce generic use (41, 
65, 90-93). These strategies are all 
potentially counter-productive especially if 
pharmaceutical companies wish public 
monies to fund their new more expensive 
medicines with increasing pressure on 
resources (4, 94). 
 
Some studies suggest that there can be 
confusion among patients if they are 
dispensed different branded generics with 
different names without explanation, 
leading   potentially   to   under-   and over- 
dosing (95), although others did not find 
such problems (96). In any event, concerns 
with generics need to be addressed to 
maximise potential savings from their 
availability. 
 
There have been varying measures across 
countries to lower the price of generics (2, 
75, 97-102) as well as enhance their use 
versus originators (1, 2, 9, 99, 103-107). 
There have also been multiple initiatives 
across countries to enhance the use of 
generics in a class versus patented products 
to conserve resources where this does not 
compromise care. Classes include the proton 
pump inhibitors (PPIs), renin-angiotensin 
inhibitors and the statins (10, 102, 108-111). 
There have also been initiatives among 
health authorities to influence the 
prescribing of generic versus patented anti- 
depressants, although recognising that there 
can  be  inter-patient  variation  (101,  112, 
113). 
 
Consequently, the aim of this paper is to 
review ongoing measures among health 
authorities across countries to enhance the 
prescribing of low cost generics, whether 
successful or not, and the implications to 
guide future activities. We will also perform 
a deeper analysis outlining recent changes in 
prescribing behaviour in Scotland and the 
outcomes to anchor key discussion points. 
 
2. Methods 
 
2.1 General measures regarding pricing 
and utilisation of generics 
 
This is principally a descriptive review of 
regulations, meta analyses and other 
relevant papers known to the co-authors 
rather than an extensive literature search of 
peer-reviewed publications regarding 
attitudes and policies towards generics as 
these have already been published (1, 9, 67, 
77, 85, 94, 97-99, 103, 104, 106, 107, 114- 
119).  In  addition,  a  history  of  time lines 
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surrounding the regulations for medicines 
including generics has also recently been 
published (71). 
 
Demand-side measures discussed in this 
paper will again be collated under the 4Es, 
namely education, engineering, economics 
and enforcement (120). These include (81, 
88, 97, 100, 111, 112, 120-131): 
• Education - activities range from 
recommended  medicines  such  as   the 
„Wise List‟ in Stockholm, Sweden, to 
printed guidelines as well as more 
intensive strategies including academic 
detailing and benchmarking physician 
prescribing habits. 
• Economics – initiatives falling under 
this category include financial incentives 
for physicians, patients or pharmacists. 
These include additional co-payments if 
patients want a more expensive 
medicine than the referenced price 
generic. 
• Engineering – this typically refers to 
managerial or organisational 
interventions such as prescribing targets 
and switching initiatives as seen with 
losartan versus other angiotensin 
receptor blockers (ARBs) once generics 
became available in England and 
Sweden. 
• Enforcement – includes regulations by 
law such as compulsory generic 
substitution or compulsory international 
non-proprietary name (INN) prescribing 
in Abu Dhabi, Lithuania, South Africa 
and Sweden as well as prescribing 
restrictions for angiotensin receptor 
blockers (ARBs) in Austria, Belgium, 
the Republic of Srpska (Bosnia and 
Herzegovina) and Sweden. 
We will first review strategies to achieve 
low prices for generics before reviewing 
different strategies to influence their 
prescribing versus originators and patented 
products in a class. 
2.2 Scotland 
 
We will also include an update on the 
influence of multiple measures in Scotland 
to enhance the prescribing of low cost 
generics versus originators and patented 
products in a class to provide a focus in the 
discussion. This builds on previous 
publications (101, 108, 132). 
 
Data from the National Health Services 
Scotland Warehouse has again been used to 
analyse trends in the utilisation and 
expenditure of key products and classes in 
Scotland. This again includes the PPIs, 
selective serotonin reuptake inhibitors 
(SSRIs), and statins. Items dispensed, which 
is typically 28 days, has been used as the 
utilisation metric in this update instead of 
defined daily doses (DDDs), which is the 
internationally recognised standard for drug 
utilisation studies (133, 134). This is 
because, items dispensed is the usual metric 
used in the United Kingdom when 
evaluatingphysician  prescribing(129). 
 
3. Results 
 
3.1 Prices ofgenerics 
 
3.1.1 Prices of generics – Europe 
 
Prices of generics can vary 36 fold or more 
across countries depending on the molecule 
and the price setting mechanisms for 
generics in that country (2, 97, 115). 
European countries also have different 
approaches to the pricing of generics (10, 
97, 108, 116). However, they can be 
typically categorised under three headings 
(97, 116, 135) including: 
• Price regulated systems (prescriptive 
pricing) – where there are established 
rules for the pricing of generics, e.g. 
Croatia, France, Norway and Poland 
(136-139) 
• Free pricing - where manufacturers are 
(relatively)  free  to  set the prices of 
international context 
 
 
 
generics, e.g. Germany, Netherlands, 
Sweden and the UK. However, there are 
typically programmes in place to lower 
prices which include compulsory 
generic substitution in  Sweden  linked 
to monthly tendering, 3-monthly 
preference pricing policies in the 
Netherlands linked to tendering and 3- 
monthly review of prices in the UK (81, 
102, 119, 132, 140) 
• Mixed approach – where a 
combination of approaches are used, e.g. 
Austria (141, 142) 
 
The various approaches can result in 
substantial differences in the prices of 
generics among different European 
countries. In European countries with 
aggressive measures to lower generic prices, 
generic prices can be as low as 2% to 4% of 
the pre-patent loss prices, e.g. Netherlands, 
Sweden and the UK for generic simvastatin 
and the Netherlands for generic omeprazole 
(81, 102, 132). 
 
The preference pricing policy was instigated 
in the Netherlands in 2008 whereby only the 
cheapest generics would be reimbursed, 
with patients covering the costs for a non- 
preferred drug (94, 102). Tenders were 
subsequently conducted for high volume 
generics resulting in further price reductions 
of between 76% to 93% for the 10 largest 
generics by volume (94). Dylst et al 
calculated that without aggressive pricing 
policies to lower the price of generic 
omeprazole, and increase its utilisation 
versus the originator, the Dutch government 
would have spent an additional €3.723 
billion on omeprazole between 2002 and 
2013, assuming similar utilisation rates and 
prices remained at pre-patent loss prices 
(41). Overall, it is estimated that the 
introduction of these policies in the 
Netherlands reduced pharmaceutical 
expenditure by €0.75-€0.90bn per year over 
the past five years (2). 
Prices for high-volume generics fell to 4 to 
13% of originator pre-patent loss prices in 
Sweden by 2009, helped by compulsory 
substitution introduced in 2002 and a 
comprehensive technical support system 
enabling pharmacies to continually stock the 
cheapest product, with prices reviewed at 
least twice a month (81). Overall savings 
from generic substitution were estimated at 
€700 million (>6.97 billion SEK) from 2002 
to the end of 2005 (81, 94). Savings are 
greater following the introduction of the 
monthly tendering process at 8 billion 
SEK/year from 2011 onwards (94). 
 
The situation regarding generic pricing is 
different in Belgium. The prices of generic 
drugs have to be lowered at least to the 
reference price to be reimbursed in 
Belgium, which was a 16% reduction versus 
pre-patent loss prices until 2002, 20% until 
2003, 26% until 2005, and currently 31%, 
with the potential for further lowering after 
that (109, 131). The only major exception 
was the statins where as a result of a public 
tendering system in January 2008, prices for 
simvastatin were further lowered by on 
average 40% (109). As a result, generic 
losartan in 2011 was only 46% below pre- 
patent loss prices and generic omeprazole in 
2009 was only 70% below pre-patent loss 
prices, whilst generic simvastatin was 85% 
below pre-patent loss prices (109, 131). 
This compares with the price of generic 
losartan in Sweden in 2011 at 90% below 
pre-patent loss prices (expenditure/ DDD) 
(128), with a similar low price in Scotland 
(Table 1). 
 
Prices of generics in Poland are regulated 
through price negotiations and 
reimbursement decisions issued by the 
Minister of Health (143). The price of the 
first generic has to be at least 25% lower 
than the solitary product (usually the 
originator) which is already included in the 
reimbursement list. Prices of all other 
generic equivalents, which subsequently 
apply for reimbursement, cannot be higher 
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than the reference price in a given reference 
group (usually one of the cheapest products 
but not always). These policies are in place 
together with the typical practice of granting 
reimbursement status to a wide spectrum of 
applying equivalent products (144). In many 
cases, this results in groups containing a 
number of generics and their originator, 
where prices do not appear to be the major 
factor in the prescribing decision. When 
coupled with insufficient educational 
activities, and a lack of promotion of 
generics, this can result in a high market 
share of expensive branded generics or 
originators to the detriment of cheaper 
generics. 
 
The size of the European country does not 
appear to be a barrier to obtaining low 
prices for generics as seen in Lithuania and 
the Republic of Srpska (122, 125) despite 
comments to the contrary (145). Overall, 
prices of generics in Europe typically fall 
further from pre-patent loss prices in high 
versus low volume generic markets (117). 
In European countries with high volume 
generic markets, Dylst et al showed prices 
among 35 active substances that had lost 
their patents dropped by 43.2% by the end 
of the study period; this compares with only 
21.6% in low volume generic markets (117). 
 
The differences in the approaches to the 
pricing of generics among European 
countries can also lead to substantial 
differences between originator and generic 
prices (98), with for instance Greece, 
Ireland and Spain displaying lower price 
differences that Denmark, Finland and 
Sweden (98). For example, sumatriptan saw 
a price decrease in Greece of 5.8% when 
compared to the originator, while in 
Denmark the variation was 95%. 
 
3.1.2 Prices of generics – Other countries 
 
There are concerns with high prices of 
generics   in   a   number   of non-European 
countries including Australia, African 
countries such as Nigeria, and Malaysia (74, 
146-149). Prices in Malaysia are not helped 
by the lack of any established pricing policy 
compared with European countries (Section 
3.1.1) (74). Prices of generics in the private 
healthcare sector in South Africa were also 
high with no formal pricing system, e.g. 
generic PPIs in 2010 were only 32% to 64% 
lower than originator prices with generic 
statins only 33% to 51% below originator 
prices in 2011 (100, 150). 
 
Recently, „Novartis Access‟ was launched 
in Kenya, which is a portfolio of 15 
principally oral medicines for patients with 
NCDs, part of Essential Medicine Lists, at a 
cost of US$1/ treatment/ month (151). This 
programme will be extended to other 
countries as it is envisaged to be 
commercially sustainable over the long term 
(151). Such initiatives should help to 
substantially lower generic prices in Africa 
and other LMICs enhancing medicine 
access. 
 
Care is needed though when introducing 
new pricing policies for generics as seen in 
South Korea. The Korean government 
implemented a new pricing policy in 2012 
in order to try and make the generic market 
more competitive through setting the same 
maximum reimbursement price between 
originators and generics (75). It was 
envisaged this would increase competition 
among generic manufacturers to lower their 
prices. However given the concerns that still 
exist regarding generics among physicians 
in Korea, the opposite was achieved. The 
price dispersion between different generics 
significantly decreased, and originator-to- 
generic utilization significantly increased 
(75). 
 
3.1.3. Prices of generics – Scotland 
 
The combination of high voluntary INN 
prescribing (see section 3.2.2), coupled with 
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measures to lower the prices of generics 
every 3 months through increased 
transparency  (see  Bennie  et  al  2012 and 
Godman et al 2013 for details (101, 132)), 
has resulted in typically low prices for a 
range of generics in Scotland (Table 1). 
 
Table 1 – Prices of generics as a percentage of pre-patent loss originator prices (amended 
from (101, 132, 152, 153)) 
 
 % of prepatent loss prices in the designated 
year 
Antipsychotics  
Risperidone 16% in 2010 
ARBs  
Losartan 12% in 2012 
PPIs  
Lansoprazole 8% in 2015 
Omeprazole 9% in 2010, 7% in 2015 
Pantoprazole 10% in 2015 
SSRIs  
Citalopram 8% in 2015 
Paroxetine 16% in 2015 
Statins  
Atorvastatin 8% in 2015 
Simvastatin 3% in 2010, 4% in 2015 
NB: ARB = angiotensin receptor blocker, PPI = proton pump inhibitor, SSRI = selective 
serotonin reuptake inhibitor 
 
3.2 Enhancing the utilisation of generics 
versus originators 
 
3.2.1 Europe 
 
Health authorities across Europe use a 
variety of measures to encourage the 
prescribing  of  generics  versus originators 
(brand name products), some of which are 
described in Table 2. Overall, multiple 
initiatives typically have a greater influence 
on future prescribing habits than more 
limited measures, in accordance with 
previous publications (10, 108, 154, 155). 
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Table 2 – Examples of measures used by health authorities across Europe to encourage the 
prescribing and dispensing of generics vs. originators (brand name molecules) 
 
Initiatives and countries Description 
Education - encouraging 
high voluntary international 
non-proprietary name 
(INN) prescribing – 
education - UK (9, 80, 101, 
132, 156, 157) 
• Multiple educational activities among physicians in the UK 
during training and post qualification, including decision 
support software and monitoring, has resulted in high INN 
prescribing 
• INN prescribing averages over 84% across all products, 
rising to over 98% for most generics (Table 3) 
• There are a recognised limited number of medicines where 
INN prescribing is not encouraged (Box 1) 
Education and economics – 
Austria 
• Several initiatives nationally to educate key stakeholders 
regarding generics, including dispelling myths such as the 
myths that existed with generic clopidogrel (61, 158) 
• The Sickness Funds in Austria also use a variety of 
approaches to enhance the prescribing of generics among 
physicians. These include training, monthly newsletters on 
changes in the reimbursement list, information events, 
personal visits to discuss prescribing habits, analysis of 
prescriptions and feedback/ benchmarking and software 
systems(105) 
• Physicians in Austria receive financial incentives for 
increased prescribing of generics versus originators (105, 
141) 
• Despite these initiatives, generic losartan accounted for 
only 46% of total losartan on a DDD basis in 2011 (142) 
Education, economics and 
engineering – France (94, 
103, 116, 136) 
• The French authorities regularly publish and update the list 
of available generics 
• Health Insurance Funds provide regular feedback to 
physicians on their generic prescribing rates 
• This combined with quality targets for physicians, 
substitution targets and incentives for pharmacists, 
financial incentives for patients as well as a prescriptive 
pricing policy for generics, led to estimated annual savings 
of €1bn in 2007, €0.905bn in 2008 and €1.01bn in 2009 
• The financial incentives for pharmacists are for reaching 
national/ regional agreed substitution targets 
Economics - financial 
incentives for patients 
(various countries) 
• There is internal reference pricing (97, 99) in the majority 
of European countries 
• Under this system, patients typically pay the additional 
cost themselves for a more expensive medicine than the 
referenced priced generic medicine to encourage the 
prescribing of cheaper generics 
• This includes the Netherlands with its preference pricing 
policy (see section 3.1.1) 
Economics – Germany • Physician prescribing costs regularly benchmarked,  with 
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(116) potential financial sanctions for continued over budget 
costs 
• Abolishing patient co-payments if reimbursed prices of the 
generic is at least 30% below current reference prices 
• Potentially reducing or abolishing co-payments if 
physicians prescribe drugs where the Sickness Funds have 
successfully negotiated contracts. The rebates, included 
those for patented drugs, resulted in estimated savings  of 
€1.3bn in 2010 
• Despite these measures, reimbursed prices for generics can 
be appreciably higher in Germany than e.g. Netherlands or 
the UK 
Enforcement - Compulsory 
INN prescribing - 
Lithuania (116, 125) 
• There is compulsory INN prescribing in Lithuania unless 
prior approval from the Hospital or Polyclinic Therapeutic 
Committee 
• Pharmacists in Lithuania are obliged to stock the cheapest 
generics with financial penalties if they do not comply 
• Overall, INN prescribing is mandatory in at least 5 
European countries (99) 
Enforcement - Compulsory 
substitution - Sweden (81, 
112, 128, 159-162) 
• There has been mandatory generic substitution in 
pharmacies in Sweden from 2002 onwards apart from a 
minority of situations (similar to the UK – Box 1), with 
patients covering the additional costs themselves for a 
higher cost medicine including the originator 
• Key stakeholder groups were typically supportive of this, 
although concerns if patients are not fully informed that 
their medicine could have a different name 
• As a result, 96% of risperidone by volume was generic, 
97.4% of total losartan was generic and 99.6% of 
venlafaxine was generic in 2011 
• Overall, generic substitution is mandatory in at least 6 
European countries (99) 
Education, economics and 
enforcement – Poland 
(143) 
• Price ceiling established by the reference product in a 
given reference group (Section 3.1.1) 
• The retail margin at the pharmacy level is currently based 
on the reference price instead of a given product‟s retail 
price 
• This can result in pharmacist‟s price indifference when 
filling a prescription for reimbursed products which have 
generic equivalents 
• This is despite compulsory informing patients (pharmacist 
obligation) on the possibility of receiving a cheaper 
reimbursed generic equivalent, whose price does not 
exceed the reimbursement limit. As a result, potentially 
reducing co-payments 
international context 
 
 
 
3.2.2 UKincluding Scotland 
Alongside high INN prescribing rates in the 
UK (Table 3), there are a small number of 
products and classes where substitution is 
not encouraged (Box 1). 
 
Box 1 – Examples where concerns with INN prescribing in the UK based on 
recommendations in the British National Formulary (BNF), the Council of the Royal 
Pharmaceutical Society and the Medicines and Healthcare Products Regulatory Agency 
(adapted from (79, 80, 84, 163)) 
 
• Amphotericin intravenous - prescribe by brand name as doses depend on the 
formulation 
• Asthma treatments: 
o Theophylline modified release preparations – typically not seen as 
interchangeable due to concerns with the clinical implications of 
switchingbetweeninequivalentpreparations 
o Beclometasone dipropionate CFC-free inhalers - care where 
administration approaches differ with different instructions 
• Calcium antagonists – care with modified release preparations as typically not 
seen as interchangeable 
• Drugs for rejection – relatively small number of eligible studies with hard to 
compare methods make recommendations difficult. However generic 
immunosuppressants such as generic cyclosporine have been on the market in 
Europe for more than 10 years with no identified serious safety signals among 
the many doses prescribed and dispensed 
• Epilepsy – in view of the different publications, the Medicine Agency recently 
issued the following advice: 
o Category 1 – phenytoin, carbamazepine, phenobarbital, and primidone – 
Physicians are advised to ensure that patients are maintained on a specific 
manufacturer‟s product 
o Category 2 – valproate, lamotrigine, perampanel, retigabine, rufinamide, 
clobazam, clonazepam, oxcarbazepine, eslicarbazepine, zonisamide, and 
topiramate - the need for continued supply of a particular product should 
be based on clinical judgement and consultation with patients taking into 
account considerations such as seizure frequency 
o Category 3 - levetiracetam, lacosamide, tiagabine, gabapentin, 
pregabalin, ethosuximide, and vigabatrin - usually unnecessary to ensure 
that patients are maintained on a specific manufacturer‟s product 
• Lithium – concerns with differences in bioavailability between different 
formulations suggesting care when considering any substitution. 
• Morphine sulphate slow release tablets – doses prescribed should be reviewed if 
the brand is changed as there may be different release patterns between the 
different formulations – similar situation regarding fentanyl transdermal 
formulations 
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Typically rates of generic prescribing across 
high volume classes including 
antidepressants, antipsychotics, PPIs, renin- 
angiotensin inhibitors and statins were 98% 
or more in recent years (Table 3). 
 
Table 3 - Percentage of generics as a percent of total molecules dispensed (DDDs or items 
dispensed) in Scotland (adapted from (101)) 
 
 
 
Class 
 
% of generic utilisation in defined daily doses 
(before 2015) and items dispensed (2015) 
Atypical antipsychotics  
Risperidone 98% in 2009 
PPIs  
Omeprazole 98% in 2010, 99.1% in 2015 
Lanzoprazole 98.8% in 2015 
Pantoprazole 99.9% in 2015 
Statins  
Simvastatin 98% in 2010, 99.1% 2015 
Atorvastatin 99.7% in 2015 
Renin-angiotensin inhibitors  
ACEIs  
Enalapril 99% in 2007 
Lisinopril 98% in 2007 
ARBs  
Losartan 99% in 2011 
SSRIs  
Citalopram 99% in 2007, 99.9% in 2015 
Fluoxetine 98% in 2007, 99.6% in 2015 
Sertraline 98% in 2007, 99.7% in 2015 
NB: ACEI = angiotensin converting enzyme inhibitor, ARB = angiotensin receptor blocker, 
PPI = proton pump inhibitor, SSRI = selective serotonin reuptake inhibitor 
 
3.2.3 Lower and Middle Income Countries 
(LMICs) 
 
The WHO proposes that optimally all 
medicines (100%) should be prescribed by 
their generic (INN) name (164). However, 
there is room for considerable improvement 
with a recent meta-analysis by Ofori-Asenso 
et al showing that the percentage of 
medicines prescribed by generic name 
across Africa was only 68.0 % (IQR 55.4– 
80.3) (165). 
This is important with Cameron et al 
demonstrating that substantial savings could 
be made among 17 LMICs from switching 
from originator brands to the lowest-priced 
generic equivalent (7). As an example in 
Thailand, implementation of generic 
substitution policies with the lowest priced 
generic would yield average annual 
potential savings of US$ 3.997million for 
seven medicines alone (7, 9). Suggested 
strategies to enhance generic uptake, that 
could be incorporated into national 
medicine policies, included substitution by 
pharmacists     as     well     as     increasing 
international context 
 
 
 
confidence in generics among key 
stakeholder groups (7). 
 
In Mexico, generics and interchangeable 
generics are currently seen as different 
products. Here, there are not only patented 
medicines and generics, but also “similar” 
and “interchangeable” medicines. This can 
confuse patients and affects how they 
perceive the safety and efficacy of generics 
overall since similar products are marketed 
as bio-equivalent, when they are not. 
Consequently, there can be mistrust in 
generics by patients and physicians (166). 
This is despite the fact that it is mandatory 
for physicians to prescribe by generic name; 
however, they can prescribe a brand name if 
the recommendation is placed between 
parenthesis. In this way, patients have the 
right tochoose. 
 
A generic drug policy were established in 
Brazil in 1999, which includes a generics 
preference policy in public purchases, 
mandatory generic substitution in public 
pharmacies, availability of generic drugs 
lists published by the regulatory agency 
(ANVISA), and educational activities 
among health professionals. Generics were 
typically introduced on average 40% lower 
than the price of the patented medicine, 
with this difference increasing to 68% 
lower in recent years. Brazil is a 
"pharmemerging" country with domestic 
companies marketing low cost generics. 
Despite these various initiatives though, 
generics only accounted for 27.3% of 
Brazilian pharmaceutical sales in 2013. The 
main barrier being the low confidence that 
physicians have in the quality of generics 
(167-169). 
 
In their recent comprehensive review, 
Hassali et al also found physicians from 
LMICs tend to have mixed views regarding 
generic medicines. The authors believed this 
may be due to differences in the health care 
systems and medicine policies, including 
how   medicines   are   funded,   as   well as 
differences in income levels. In addition, the 
extent of educational initiatives among key 
stakeholder groups as well as available drug 
information sources (67). Concerns with 
therapeutic failure among physicians in 
Nigeria, especially among locally produced 
generics, also potentially discourages their 
use (63). There are also concerns between 
the perceived and actual quality of generics 
in South Africa, again potentially affecting 
their use (3). 
 
Having said this, there have been only a 
limited number of policy evaluations to date 
to determine which of the potential policies 
and measures LMICs could introduce to 
increase the utilisation of generic medicines 
in their countries (106). Ensuring a 
functioning medicines regulation system for 
marketing authorisation, creating a robust 
market as well as aligning incentives for all 
key stakeholder groups appear necessary 
prerequisites for increasing the utilisation of 
generics in LMICs (106). 
 
Truter in her recent study found increasing 
use of generic meprobamate analgesic 
combination in a retrospective study of a 
medical health insurance claims database. 
There is compulsory generic substitution in 
South Africa unless otherwise specified by 
the physician or the patient prefers to pay 
for the more expensive originator. This is 
unlikely in this case in view of the price 
difference (170, 171). Her study found that 
the originator constituted only 3.7% of the 
analgesics prescribed (average cost was 
R30.42) compared to 70.6% for the most 
popular branded generic, with a cost of 
R11.65 (170, 171). 
 
However, there has been low use of generics 
versus originators among hospitals in China, 
where most medicines are dispensed, when 
compared to a number of European 
countries (172-174), e.g. generic statins 
accounted for only 9% to 10 % of total 
statins in recent years in hospitals in China 
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(175). The low use of generics is 
exacerbated by the need for hospitals to 
make money from drug procurement for 
their sustainability and physicians to 
supplement their income, with this incentive 
system also stimulating overuse of 
injections (174, 176-178). Having said this, 
Li et al recently demonstrated that patients 
could be successfully switched from 
imported originator anti-depressants to 
locally produced generics following 
education and psychological support 
without affecting subsequent care (179). 
 
In recent publications from Malaysia, Chua 
et al demonstrated that private GPs in 
Malaysia have largely accepted generic 
medicines.    However,    they    still   have 
concerns regarding their reliability and 
quality necessitating further education and 
reassurance (72). Kumar et al also recently 
demonstrated that the majority of the 
physicians among private medical centres in 
Malaysia had negative perceptions about the 
safety and efficacy of generic medicines, 
impacting on their use (74). Similar 
approaches are needed to address this 
including reassurance of the quality of 
generics as well as physician education (74). 
There are also still concerns with generic 
substitution in Malaysia, enhanced by fears 
regarding the efficacy and safety of generics 
(74). This resulted in Hassali et al 
developing a list of requirements that should 
be met to enhance successful generic 
substitution (Box 2). 
 
 
Box 2 – Potential requirements to successfully implement a generic substitution policy 
(adapted from (118)). 
 
 
3.2.4 Other countries 
 
In 2012, Japan modified its prescription 
format to allow generic substitution for 
individual  medicines  to  encourage greater 
generic prescribing, although physicians can 
also indicate „no substitution‟ if concerns 
(24). Generic substitution is encouraged as 
it is estimated successful implementation 
would   result   in   estimated   savings    of 
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Japanese Yen (JPY) 1.3 trillion per year. 
This is coupled with financial incentives for 
physicians and pharmacists to enhance their 
generic prescribing and dispensing (9). 
However despite these moves, the utilisation 
of generics remains low in Japan. This is 
because there are still negative perceptions 
towards generics, pharmacists are reluctant 
to recommend them, and there is currently 
limited cost differences between generics 
and originators in practice (9). 
 
However, care is needed when introducing 
policies such as compulsory INN 
prescribing as recently seen in Abu Dhabi 
(130). Compulsory INN prescribing was not 
backed up by multiple policies among 
physicians to enhance the preferential 
prescribing of multiple-sourced medicines 
in the class. In addition, pharmacists could 
still dispense different brands of the same 
product and be reimbursed in full. As a 
result, there was increased utilisation of 
patent protected products and the envisaged 
savings were not attained (130). 
 
3.2.5 Addressing concerns with the efficacy 
and safety of generics 
 
As seen, education and effective regulatory 
systems are key to addressing concerns with 
generics, where these exist, given the 
extensive number of publications that have 
demonstrated similar effectiveness between 
generics and originators for generics 
meeting agreed quality standards (3, 24, 67, 
106). 
 
Concerns with the complexity, production, 
and distribution of generics has highlighted 
the need for convergence of regulations. 
This has resulted in the instigation of     the 
„International Generic Drug Regulators 
Programme‟, which comprises regulatory 
bodies from several countries as well as the 
WHO (24). 
To help address concerns in the US, the 
FDA in 2014 issued 18 warning letters to 
generic manufacturers oversees, and in 2015 
undertook multiple inspections in for 
instance in India as well as increasing its 
office staff there (24). The FDA has also 
banned generics manufactured at several 
facilities in India until improvements, as 
well as fined manufacturers for selling 
adulterated generics. The EMA has also 
recommended countries to withdraw a large 
number of generic medicines whose pivotal 
trials were performed fraudulently with 
GCP variations by one Indian contract 
research organisation, leading to concerns 
with data quality (24). Such initiatives will 
continue through steadily enlarging 
authorities‟ inspection activities. In addition, 
the Central Drugs Standard Control 
Organization (CDSCO) in India will soon 
start making surprise inspections among 
manufacturing sites to improve the quality 
(24). 
 
Khan et al recently suggested ways to 
improve the quality of generics in Pakistan 
in view of concerns with the quality of the 
active ingredient (78). Concerns with their 
quality resulted in some manufacturers 
increasing the quantity of the active 
ingredient in the manufacturing process, 
which is not in the best interest of any key 
stakeholder group as this could lead to over- 
dosing. 
 
It should be borne in mind though that 
efficacy and safety concerns have also 
arisen with different batches of patented 
products (71). 
 
3.3 Increasing the prescribing of generics 
(multiple sourced products) vs patented 
products in a class 
 
There are also a variety of measures that 
health authorities have used to encourage 
physicians to increase their prescribing of 
generics versus patented products in a class 
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to save resources without compromising 
care (53, 55, 59, 180-182). These measures 
are more prevalent in countries with high 
volumes of generics (117) and involve (i) 
educational initiatives among physicians 
including guidelines, academic detailing and 
benchmarking physician prescribing habits; 
(ii) incentive schemes (financial incentives); 
(iii) encouraging switching as well as 
prescribing targets (engineering) and (iv) 
prescribing restrictions (enforcement) (59, 
77, 103, 108, 110, 111, 128, 129, 136, 138, 
158, 183, 184). Classes include the proton 
pump inhibitors (PPIs), renin-angiotensin 
inhibitors and the statins (1, 59, 110, 111, 
124, 185, 186). In addition, antidepressants 
in certain countries (101, 112). However, 
there are classes where health authorities are 
not active with influencing prescribing 
patterns. These include the antipsychotics 
(Section 3.3.4). Again, multiple initiatives 
typically have a greater influence on future 
prescribing habits than a more limited 
number of measures (10, 108, 154, 155). 
 
In the US in 2005, it was estimated that 
US$20billion could be saved annually in 8 
medicine classes among the commercially 
insured patients if there was therapeutic 
interchange to guideline adherent medicines 
(46). More recently, it was estimated by 
Gellad et al that Medicare could save 
US$1.4billion alone each year for patients 
with diabetes if prescribing mirrored the VA 
(Veterans Administration) system 
combining generic substitution and 
therapeuticinterchange(187). 
 
3.3.1 PPIs across Europe excluding 
Scotland 
 
Multiple demand-side initiatives were 
instigated in a number of European 
countries to increase the prescribing of 
generic versus patented PPIs, combined 
with measures to lower generic prices 
(Section 3.1), to enhance prescribing 
efficiency  as  no  perceived  difference  in 
effectiveness between the different PPIs (10, 
46, 108). Typically, countries that instigated 
multiple policies limited the prescribing of 
patented PPIs versus those countries with 
more limited demand-side measures (1, 10, 
108). This is illustrated by: 
 
• Sweden versus Ireland (10, 108) 
o Multiple demand side measures, 
including education, economics, 
and engineering, appreciably 
increased the prescribing of 
omeprazole in Sweden once 
generics became available and 
limited the utilisation of 
esomeprazole to less than 20% 
on a DDD basis by the end of 
2007 
o There was limited demand-side 
measures in Ireland. As a result 
of commercial activities, 
utilisation of omeprazole 
decreased following generic 
avaialbility with esomeprazole 
increasing, with the utilisation of 
both approximately 30% of total 
PPI utilisation in 2007 
o These activities, combined with 
the measures to lower the prices 
of generics in Sweden (Section 
3.1), resulted in reimbursed 
expenditure for the PPIs in 
Sweden decreasing by 49% in 
2007 vs. 2001 despite utilisation 
increasing by 53%. In Ireland 
(GMS population – greater co- 
morbidity than the normal 
population), utilisation increased 
by 2.4 fold during this period 
and expenditure increased 2.6 
fold 
o Consequently, reimbursed 
expenditure (Euros/ 1000 
inhabitants/ year) in Ireland in 
2007 was over 10 fold greater at 
over €60,000 versus €5832 for 
Sweden 
  
 
 
 
• Netherlands (102) 
o Aggressive measures to lower 
generic prices coupled with 
multiple demand side measures 
in the Netherlands, including 
education, economic and 
engineering initiatives, (Section 
3.1), led to low utilisation of 
esomeprazole stabilising at 15% 
of total PPI utilisation in 2010 
o As a result, reimbursed 
expenditure for the PPIs fell by 
58% in 2010 compared with 
2000 despite a 3 fold increase in 
utilisation 
 
The situation in Ireland compares with 
Norway where esomeprazole dominated PPI 
prescribing  shortly  after  its  launch   with 
 
limited demand-side measures (138). There 
was though increasing utilisation of 
pantoprazole especially after the 
introduction of prescribing restrictions for 
esomeprazole and the preferred product 
status for pantoprazole in February 2007. 
The utilisation of esomeprazole fell after 
this although rose again in 2009 compared 
with 2008 (Table 4). This was perhaps not 
surprising as specialists in Norway have to 
verify the diagnosis and recommend therapy 
before PPIs can be reimbursed, and they 
were not subject to these restrictions. In 
addition, prescribing by physicians in 
ambulatory care is principally on trust, with 
limited follow by the health authorities, and 
they are reluctant to change prescriptions 
emanatingfrom specialists (138). 
 
Table 4 – Utilisation of PPIs in Norway 2001 to 2009 (DDDs/ 1000 inhabitants/ day-138) 
 
 2001 2003 2005 2007 2008 2009 
Omeprazole 8.98 5.03 4.38 5.61 6.42 6.67 
Esomeprazole 3.6 10.17 13.64 13.73 13.4 14.34 
Pantoprazole 0.25 0.5 0.8 4.32 6.77 8.18 
Lanzoprazole 4.04 4.75 5.66 6.13 6.49 6.53 
Total PPIs 16.87 20.45 24.48 29.79 33.08 35.72 
 
3.3.2 Renin-angiotensin inhibitors across 
Europe 
 
3.3.2.1 Angiotensin converting enzyme 
inhibitors (ACEIs) 
 
ACEIs can produce a cough in some 
patients, which can be bothersome. This 
argument has been used as the main 
justification for increasing the prescribing of 
ARBs (188, 189), which are typically 
substantially more expensive than generic 
ACEIs although the effectiveness and safety 
of both are similar (111, 190). Nevertheless, 
prospective clinical studies had shown 
coughing only occurs in approximately 10% 
of patients, and only 2% to 3% of patients in 
ACEI  clinical  trials  actually discontinued 
treatment due to coughing (111, 189). As a 
result, considerable resources can be 
conserved with limiting the prescribing of 
patented angiotensin receptor blockers 
(ARBs) versus generic ACEIs as seen for 
instance in Austria, Croatia and Scotland 
(111). 
 
The introduction of prescribing restrictions 
for patented ARBs in Austria and Croatia 
restricting their prescribing to patients 
intolerant to ACEIs, such as those with 
excessive coughing, limited their utilisation 
in practice (111). This compares with 
Portugal with appreciably higher utilisation 
of ARBs in 2007 with limited demand-side 
measures combating ARB manufacturers‟ 
marketing  activities  (Table  5).  Low ARB 
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utilisation was also seen in Scotland with 
multiple initiatives to encourage the 
prescribing of low cost generic ACEIs first 
line (111). There was greater follow-up of 
prescribing restrictions in Croatia compared 
with   Austria,   which   included   access to 
patients‟ histories to check for abuse 
coupled with potential fines for physicians if 
this was seen. As a result, more limited 
utilisation of ARBs in Croatia compared 
with Austria between 2001 and 2007 (Table 
5) (101, 111). 
 
Table 5 – ARB utilisation as a percentage of total renin-angiotensin utilisation (in DDDs) 
2001 to 2007 (adapted from (101, 111)). 
 
 2001 2002 2003 2004 2005 2006 2007 
Austria 15.3 17.9 18.9 20.7 22.4 23.6 24.8 
Scotland 11.6 12.9 14.5 16.1 17.2 18.2 18.8 
Croatia 2.1 2.5 5.8 9.2 11.8 14.0 13.2 
Portugal 19.8 24.7 29.1 33.3 36.4 40.2 44.5 
 
These various measures resulted in 
reimbursed expenditure (Euros/ 1000 
inhabitants/ year) remaining relatively stable 
in Austria, Croatia and Scotland for the 
renin-angiotensin inhibitor drugs during this 
period  despite  increasing  volumes  (111), 
e.g. the utilisation of renin-angiotensin 
inhibitors increased 159% from 2001 to 
2007 in Scotland during this period (101, 
111). This compares with Portugal where 
expenditure increased by 155% during this 
period (111). 
 
Prescribing restrictions for ARBs were also 
introduced in the Republic of Srpska (122). 
These included patients experiencing 
unwanted side-effects with ACEIs, 
specialist recommendation for switching, 
monitoring of restrictions by pharmacists 
before dispensing and a 50% co-payment 
for selected ARBs otherwise 100% co- 
payment. These combined activities limited 
ARB prescribing in practice in the Republic 
to 2% of total renin-angiotensin inhibitors in 
2010 (122). Similarly, appreciably higher 
co-payments for the ARBs in Serbia (50%) 
due to higher requested acquisition costs 
than generic ACEIs, compared with a co- 
payment of 50 cents/ pack for ACEIs, 
resulted in ARBs again only accounting for 
2% of total renin-angiotensin inhibitor drugs 
in Serbia in 2011 (190). 
 
3.3.2.1 Angiotensin receptor blockers 
(ARBs) 
 
There were considerable activities in 
Austria, Belgium, Denmark, and Sweden, to 
enhance the prescribing of generic losartan 
versus patented ARBs following their 
availability, with limited measures in 
countries such as Scotland (110). Activities 
included (110, 128, 131, 142, 191): 
• Austria - economics and enforcement 
including prescribing restrictions 
removed for losartan but not the other 
ARBs with potential financial sanctions 
for physicians for abuse 
• Belgium - economics and enforcement – 
physician prior approval needed to 
prescribe patented ARBs else 100% co- 
payment; prescribing restrictions lifted 
for losartan 
• Denmark - enforcement - delisting of 
all ARBs other than losartan from the 
reimbursedlist 
• Sweden - education, engineering, 
economics and enforcement including 
academic detailing, prescribing targets, 
therapeutic        switching,       financial 
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incentives, and prescribing restrictions 
lifted for losartan but not patented ARBs 
 
These initiatives resulted in ARB 
expenditure in Sweden falling by 26% by 
August 2011 (accumulated 6-monthly basis) 
despite a 16% increase in overall utilisation 
versus the pre-patent loss situation (128). 
 
However, there were limited demand-side 
measures in countries such as Scotland 
(152). This is because the Health Boards 
already had a number of quality  initiatives 
in place, they did not want to confuse 
physicians from encouraging ACEIs first 
line, they would obtain appreciable savings 
from generic losartan with high INN use 
and associated low prices (Tables 1 and 3), 
and other ARBs would shortly lose their 
patent (152). As a result, there was no 
change in the prescribing of losartan as a 
percentage of total ARB in Scotland versus 
the other European countries with active 
measures in place, which were all 
significant (110, 128, 131, 142, 191) (Figure 
1). 
 
Figure 1 – Prescribing of losartan as a percentage of total ARBs (DDD basis) before and after 
the availability of generic losartan (Month 0) (adapted from (110)) 
 
 
A similar situation was seen in England to 
Scotland until active switching policies 
were instigated (129). 
 
3.3.3 Statins across Europe excluding 
Scotland 
 
Again, multiple demand-side initiatives 
were instigated by a number of European 
countries to increase the prescribing of 
generic versus patented statins, combined 
with measures to lower generic prices 
(Section 3.1), to enhance prescribing 
efficiency. This was because the various 
statins were seen as essentially similar by 
health authorities at therapeutic doses (10, 
108, 186, 192). 
Typically, countries that again instigated 
multiple policies limited the prescribing of 
patented statins versus those countries with 
more limited demand-side measures (1, 10, 
108). This is illustrated by: 
 
• Sweden versus Ireland (10, 108) 
• Multiple demand-side measures in 
Sweden (Education, economics and 
engineering) resulted in simvastatin 
utilisation increasing to 74% of total 
statin utilisation by the end of 2007 
with patented statins (atorvastatin 
and rosuvastatin) limited to 21% 
totalutilisation 
• Again limited demand-side measures 
in Ireland resulted in the utilisation 
of atorvastatin and rosuvastatin 
rising     appreciably     in     Ireland 
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two statins combined accounted  for 
nearly 80% of total statin utilisation 
(DDD basis) in Ireland in 2007 
(GMS population) 
• This resulted in reimbursed 
expenditure in Ireland increasing 4.9 
fold between 2001 and 2007 with 
utilisation increasing 7.3 fold, 
compared with a 39% reduction in 
reimbursed expenditure in Sweden 
alongside a 3.2 fold increase in 
utilisation 
• As a result, reimbursed expenditure 
(Euros/ 1000 inhabitants/ year) in 
Ireland in 2007 for the statins was 
again over €60,000 versus €5,192 
for Sweden 
• Netherlands (102) 
• Again multiple demand side 
measures to limit the prescribing of 
patented statins, with atorvastatin 
comprising only 27% of total statin 
utilisation (DDD basis) in 2010 
• This coupled with supply side 
measures to lower generic prices 
(Section 3.1.1) resulted in 
reimbursed expenditure for the 
statins falling by 14% in 2010 vs. 
2000 in the Netherlands despite a 3.8 
fold increase in utilisation 
• Austria and Norway (59, 138, 193) 
• Prescribing restrictions were 
introduced for patented statins in 
both Austria and Norway to limit the 
prescribing of patented statins 
following the availability of generic 
simvastatin 
• In Austria, physicians needed the 
permission of the Chief Medical 
Officer of their Social Insurance 
Fund for atorvastatin to be 
reimbursed, otherwise 100% co- 
payment 
• In Norway, active therapeutic 
switching was encouraged alongside 
prescribing   restrictions.  However, 
limited   follow   up   of    physician 
prescribing by the health authorities. 
However, physicians needed health 
authority permission if they wished 
to prescribe lower strength 
atorvastatin (10 and 20mg) and 
patients be reimbursed 
• As a result of the differences in the 
follow-up of the restrictions, 
utilisation of patented statins fell 
from 31.6% of total statins in 2003 
(year before restrictions – DDD 
based) in Austria to 10.9% in 2007, 
a 66% reduction. In Norway, their 
utilisation fell from 46.2% of total 
statins (full year before restrictions) 
in 2004 to 26.2% in 2008, a 
reduction of 44% 
 
3.3.4 Atypical antipsychotics 
 
It is generally recognised by health 
authorities that there are classes where it can 
be difficult for them to instigate demand- 
side measures to try and increase the 
prescribing of generics versus patented 
products in a class. One such class is the 
atypical antipsychotic drugs for treating 
schizophrenia and bipolar disease. Experts, 
as well as health authorities, suggest 
treatment should be tailored to individual 
patients (194-196). 
 
This was seen in practice in a recent study, 
which showed a consistent decrease in 
risperidone utilisation among European 
countries as a percentage of selected 
atypical antipsychotics (DDD basis) 
following the availability of generic 
risperidone (113, 153, 161, 196, 197). 
Consequently, health authorities generally 
need to wait until more atypical 
antipsychotics lose their patents before they 
see significant reductions in expenditure, 
which is already happening (196). The only 
exceptions to this are initiatives to enhance 
the  prescribing  of  different  formulations 
international context 
 
 
 
 
value. This was seen in Belgium where 
there  has  been  greater  scrutiny  over  the 
 
(112). 
restrictions 
prescribing of more expensive long-acting 
risperidone injections following oral generic 
risperidone at appreciably lower costs (197). 
This resulted in its reduced utilisation in 
recent years versus other formulations of 
risperidone, which is continuing (197). 
 
3.3.5 Prescribing restrictions 
 
As seen in Table 5 and Section 3.3.2.1, 
restricting the prescribing of ARBs in 
Austria, Croatia, and the Republic of 
Srpska, appreciably limited their prescribing 
versus countries with limited demand-side 
measures, e.g. Portugal. The prescribing 
restrictions for patented statins in Austria 
also appreciably reduced their utilisation 
(Section 3.3.3). 
 
However, the greater intensity of follow-up 
of ARB prescribing restrictions in Croatia 
and the Republic of Srpska, resulted in 
greater utilisation of generic ACEIs in 
Croatia and the Republic of Srpska versus 
Austria. Similarly greater follow-up of 
prescribing restrictions for patented statins 
in Austria compared with Norway resulted 
in appreciably lower utilisation of patented 
statins in Austria (111, 122, 138). Limited 
follow-up of prescribing restrictions for 
esomeprazole in Norway (Section 3.3.1) 
also resulted in greater utilisation of 
esomeprazole than initially envisaged (138). 
 
A similar situation was seen in Sweden 
where the authorities restricted the 
prescribing of patented duloxetine following 
the availability of generic venlafaxine as its 
effectiveness and cost could not justify first 
line use (112). However, there was limited 
follow-up of the prescribing restrictions 
among the authorities in practice. This 
resulted in no change in duloxetine 
utilisation (DDD basis). However, there was 
a  significant  increase  in  the utilisation of 
The timing of prescribing restrictions is also 
important. Prescribing restrictions were 
recently introduced for patented statins in 
Sweden. However, they had limited 
influence on subsequent utilisation patterns 
in practice (198). This may be due to the 
fact that they were introduced some six 
years after intensive activities to encourage 
the preferential prescribing of generic 
statins (Section 3.3.3) (108). 
 
3.3.6 Scotland 
 
• PPIs 
 
There was typically limited prescribing of 
patented esomeprazole in Scotland in recent 
years with multiple demand-side measures, 
which included formularies, academic 
detailing, prescribing targets and financial 
incentives (132). As a result, esomeprazole 
comprised only 5.3% to 7.1% of total PPI 
utilisation (DDD basis) between 2002 and 
2010 compared with omeprazole, which 
comprised 67% of total PPI utilisation in 
2010 (132). 
 
This has continued with esomeprazole 
comprising 7.7% in 2011 and 6.4% in 2012 
of total omeprazole and esomeprazole, i.e. 
before generic esomeprazole utilisation 
became available, versus 6.29% in 2002 
(items dispensed). 
 
As a result of these initiatives, coupled with 
measures to lower the price of generics 
(Table 1) and ensure high INN prescribing 
(Table 3), PPI expenditure fell from 
GB£56.49 million in 2001 in Scotland to 
GB£18.06 million in 2015, a drop of 68%. 
At the same time, utilisation increased 2.91 
fold to 5.23 million items dispensed in 
2015. Reimbursed expenditure for the PPIs 
in 2015 would have been GB£146.18 
million  greater  assuming  no  generic PPIs 
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and the average cost/item dispensed in 2015 
remained at 2001 levels. 
 
• SSRIs 
 
Multiple demand side initiatives in Scotland 
between 2001 and 2007 limited the 
prescribing of escitalopram compared with 
countries with less demand side measures 
(101). For example, escitalopram comprised 
27.1% of total SSRI prescribing in Ireland 
by the end of 2007 versus only 7.0% in 
Scotland. As a result, SSRI expenditure fell 
by 59% in Scotland in 2007 compared with 
2001 but increased by 72% in Ireland. This 
was despite a 2.37 fold increase in SSRI 
utilisation during this period in Scotland 
(101). 
 
The same prescribing patterns have 
continued with anything a reduction in the 
utilisation of escitalopram over time from 
15.6% of total citalopram and escitalopram 
use in 2007 to 7.3% in 2012, 6.4% in 2013 
and 5.8% in 2014. As a result of these 
initiatives, coupled with measures to lower 
the price of generics (Table 1) and ensure 
high INN prescribing (Table 3), SSRI 
expenditure fell from GB£28.937 million in 
2011 to GB£11.551 million in 2015, a drop 
of 60.1%. During this time, utilisation 
(items dispensed) increased from 1.3 
9million in 2001 to 2.95 million in 2015, 
and increase of 112%. 
 
• Statins 
 
There again were multiple measures to 
increase the prescribing of multiple sourced 
(generic) statins. This resulted in 
simvastatin   dominating   statin utilisation, 
e.g. 57% to 58% of total statin utilisation 
(DDD basis) from 2007 to 2010. Concurrent 
with this, there was stabilisation of 
atorvastatin and rosuvastatin utilisation at 
40% of total statin utilisation (132). 
Since the availability of generic atorvastatin 
in 2012, its prescribing has appreciably 
increased as a result of initiatives to switch 
patients from rosuvastatin to atorvastatin as 
well as encourage the prescribing of 
simvastatin and atorvastatin first line, 
particularly higher strength atorvastatin 
(199-203). This led to the utilisation of 
rosuvastatin falling from 262,409 items 
dispensed in 2011 to 217,791 in 2015 in 
Scotland, a 16. 8% fall, whilst the utilisation 
of atorvastatin rose from 1,149,459 items 
dispensed in 2011 to 1,637,000 in 2015. As 
a result, the utilisation of rosuvstatin fell 
from 5.7% of total statins (items dispensed) 
in 2011 to 4.5% in 2015. 
 
Following the variety of initiatives to 
increase the prescribing of low cost generic 
statins (Tables 1 and 3), statin expenditure 
in Scotland fell from GB£43.39 million in 
2001 to GB£19.10 million in 2015, a drop 
of 56%. At the same time, utilisation 
increased 4.03 fold to 4.89 million items 
dispensed in 2015. Reimbursed expenditure 
for the statins in 2015 would have been 
GB£155.80 million more assuming no 
generic statins and the average cost/ item 
dispensed in 2015 remained at 2001 levels. 
 
4 Discussionandconclusions 
 
Increasing the use of generics is essential to 
maintain equitable and comprehensive 
health care in Europe given increasing 
pressure on resources, with case histories 
demonstrating the extent of potential 
savings that can be achieved. Countries are 
learning from each other, and this will 
continue (1). 
 
The first step in this process is ensuring 
good quality generics for patients as seen in 
Europe and the US. This can be achieved 
through strengthening the registration 
system, including factory inspections, and 
the tests performed in accordance with 
Kaplan et al and others (106). Regulations 
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and initiatives supporting the production of 
good quality generics can also help 
countries with exports, which is a concern 
currently in countries such as Pakistan (78). 
Concurrent with this is education of all key 
stakeholder groups that there should be no 
difference in patient care once the quality of 
generics is assured. The ultimate aim is to 
achieve high INN prescribing rates as seen 
in the UK (Table 3) for the ARBs, PPIs, 
SSRIs and statins, which are very close to 
the 100% target set by the WHO (165). 
Encouraging INN prescribing is seen as 
beneficial to reduce patient confusion if 
different branded generics are dispensed at 
each occasion (95, 129). However, in some 
countries this will take time as current IT 
systems are based around branded generics, 
e.g. Sweden. Once instigated, apart from a 
small minority of clinically justified 
situations (Box 1), the focus should be on 
efficient registration and reimbursement 
systems as well as quality control. 
 
The pricing of generics is also a key 
consideration to sustainability and 
affordability especially in LMICs, with 
companies now showing the way on 
potential low costs for producing oral 
generics with economies of scale (Section 
3.1). The Netherlands, Scotland (Table 1) 
and Sweden (Section 3.1) provide examples 
of ways to lower prices of generics when 
linked to increased utilisation. However in a 
number of countries, this has to be balanced 
against supporting the development of local 
manufacturing facilities which can add to 
costs. In addition, low prices for generics 
have to be balanced against their availability 
(2). If prices of generics become too low, 
they become uneconomical making drug 
shortages more likely (38, 204). 
 
Pricing policies for generics have to be 
thought through, and coupled with demand- 
side measures, to ensure expectations are 
met. Otherwise there could be 
disappointment  as  seen  in  China  with its 
current incentive systems (Section 3.2.3). 
Price cuts can bring about substantial 
savings; however, these are short lived 
without also looking at demand-side 
measures (75). 
 
There are multiple ways that health 
authorities can increase the prescribing of 
generics versus originators (Table 2). As 
mentioned, encouraging INN prescribing is 
advocated by the WHO and others (165). 
This includes encouraging INN prescribing 
voluntarily through education of both health 
professionals and patients, and follow-up 
apart from a limited number of cases (Box 
1), as seen in the UK (Table 1). 
Alternatively, mandating this as seen in Abu 
Dhabi and Lithuania (125, 130). However 
care is needed as seen in Abu Dhabi else 
again the envisaged goals will not be 
achieved (Section 3.2.4). A number of 
countries have also instigated compulsory 
generic substitution, including South Africa 
and Sweden (140, 159, 170); alternatively 
encouraged pharmacists to substitute, e.g. 
France (Table 1) (136). Hasseli et al provide 
guidance (Box 2) for countries 
contemplatingsuchmeasures. 
 
There are also multiple initiatives that can 
be introduced by health authorities to 
encourage the prescribing of multiple 
sourced products in a class versus patented 
ones (Section 3.3).   As seen (Sections 3.1, 
3.2 and 3.3), both supply as well as multiple 
demand-side reforms are essential to 
maximise prescribing efficiency. The 
multiple supply- and demand-side measures 
in Scotland have resulted in considerable 
savings (Section 3.2.6) for the various 
classes despite appreciably increased 
utilisation, providing direction to others. 
The multiple measures in Scotland also 
stabilised renin-angiotensin inhibitor 
expenditure between 2001 and 2007 despite 
a 159% increase in utilisation (Section 
3.3.2.1). 
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Demand-side measures appear to be 
complementary. Countries that have 
instigated only a limited number of demand- 
side measures typically fail to combat 
pharmaceutical company pressure. This was 
seen in Ireland with the PPIs, SSRIs and 
statins versus Scotland and Sweden (3.3.1, 
3.3.3, 3.3.6), Norway with esomeprazole 
even with prescribing restrictions (Table 4) 
and Portugal with the ARBs (Table 5). In 
Scotland, where there was no change in 
ARB prescribing patterns following generic 
losartan, with no specific activities 
encouraging its preferential prescribing 
versus patented ARBs (Figure 1) (152), 
suggests no „spill over‟ effect of health 
authority activities across classes even if 
they are closely related such as the renin- 
angiotensin inhibitors. Physicians in 
Scotland were good at preferentially 
prescribing generic ACEIs versus patented 
ARBs (Table 5); however, this did not 
translate into increased prescribing of 
generic losartan versus patented ARBs 
when it became available. Overall, the 
multiple demand-side measures in Scotland 
to limit ARB prescribing appeared just as 
effective as prescribing restrictions with 
follow-up in Croatia (Table 5). 
 
There are similar considerations when it 
comes to prescribing restrictions. These 
need to be followed up by health authorities 
to maximise their impact, else health 
authorities could be disappointed in the 
outcomes (Section 3.5). However, it is 
acknowledged there are some classes where 
it is difficult for health authorities to 
introduce multiple measures such as the 
atypical antipsychotics (Section 3.3.4) 
 
Concentrating on one reform, i.e. either 
supply or demand side measures, but not 
both, can also reduce potential efficiency 
gains from the availability of generics. This 
was seen with price cuts in Korea for 
medicines to treat patients with 
hypercholesterolaemia    which    failed  to 
achieve the desired results with appreciably 
increased use of atorvastatin following 
generics as well as more expensive lipid 
lowering drugs (205). In Germany in 2007, 
there was very limited utilisation of 
atorvastatin following reference pricing for 
the class in 2003 at just 2% of overall statin 
utilisation (185). This compares with 21% 
and 33% respectively on a DDD basis for 
atorvastatin and rosuvastatin in Sweden and 
England in 2007 (108). However, 
expenditures were similar or greater in 
Germany when adjusted for population sizes 
due to higher expenditure/ DDD for 
simvastatin. 
 
Above all, the commitment of health 
authorities to promote the appropriate use of 
medicines including generics, coupled with 
the political will to pursue changes in 
existing pharmaceutical policies, is very 
important to achieve desired savings and 
medicine access. 
 
We accept there are limitations with this 
paper. This includes the fact that we did not 
undertake a systematic review of published 
studies as many such reviews and meta 
analyses have already been performed. 
However in view of the consistency of our 
findings, we believe our findings are robust 
and provide direction to others. 
 
In conclusion, multiple measures and 
initiatives are needed to ensure low cost for 
generics and enhance their utilisation versus 
originators and patented products in a class. 
This is essential to attain or ensure universal 
health care as well as increase affordability 
of medicines. Countries are learning from 
each other, and this will continue. 
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